Post by
fox7mf on Oct 23, 2023 9:23am
Roche to acquire Telavant for $7.1b.
Telavant holdings is currently owned by PFE and is having promising results treating crohns. Where's Oncy's deal? We wait...I guess.
Comment by
Noteable on Oct 23, 2023 12:21pm
https://www.thestreet.com/investing/stocks/roivant-surges-as-ramaswamy-found-firm-reaches-7-1-billion-roche-deal
Comment by
Noteable on Oct 23, 2023 12:29pm
June 2023 - Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b
Comment by
Noteable on Oct 23, 2023 12:38pm
“.... results were further enhanced in the roughly 60% of patients selected by a prospectively defined biomarker which had been identified in the earlier Phase 2a TUSCANY study. ”
Comment by
Noteable on Oct 23, 2023 12:52pm
On the strength of biomarker data in Riovants Phase2b study , Roche is very likely looking towards filing an Accelerated Approval with the FDA for Telavant.
Comment by
13X2413 on Oct 23, 2023 9:44am
Oncy's deal? Apparently todays news wasn't highly thought of. Why would there be interest from anybody if everything they release knocks the share price further down. To me, it looks like ONC doesn't have much to offer. Price action=public sentiment.